Acetazolamide

Generic Name: Acetazolamide

Drug Type: Small Molecule

Chemical Formula: C_₄H_₆N_₄O_₃S_₂

CAS Number: 59-66-5

Unique Ingredient Identifier: O3FX965V0I

Background: One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Indication: For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma

Associated Conditions: Acute angle-closure glaucoma, Edema, Familial periodic paralysis, Generalized Tonic-Clonic Seizures, Metabolic Alkalosis, Open Angle Glaucoma (OAG), Other and unspecified effects of high altitude, Cystine renal calculi, Drug-induced edema, Nonuveitic secondary glaucoma, Salicylate intoxication

Associated Therapies: Urine alkalinization therapy

Clinical Trials

Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC

Phase 3

Conditions: HCC

Interventions: Drug: Acetazolamide Levamisole

First Posted Date: 2020-11-02

Last Posted Date: 2020-11-02

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 50

Registration Number: NCT04611373

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Impact of Acetazolamide in Reducing Referred Postoperative Pain

Phase 1

Completed

Conditions: Men
Prostate Cancer

Interventions: Other: Placebo
Drug: Acetazolamide

First Posted Date: 2020-07-14

Last Posted Date: 2022-09-23

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 33

Registration Number: NCT04470843

Locations: 🇺🇸
Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States

Acetazolamide for the Prevention of Post Operative CSF Leak

Phase 2

Withdrawn

Conditions: Cerebrospinal Fluid Leak

Interventions: Drug: Acetazolamide

First Posted Date: 2020-04-17

Last Posted Date: 2021-12-14

Lead Sponsor: University of Miami

Registration Number: NCT04351061

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Treatment of Chronic Mountain Sickness

Not Applicable

Conditions: Hypoxia, Altitude

Interventions: Drug: Placebo oral tablet
Drug: Atorvastatin
Drug: Acetazolamide

First Posted Date: 2020-01-31

Last Posted Date: 2021-08-20

Lead Sponsor: Centre d'Expertise sur l'Altitude EXALT

Target Recruit Count: 60

Registration Number: NCT04251364

Locations: 🇫🇷
Association EXALT, UM Sport Pathologies, Hôpital Sud, Avenue Kimberley, Échirolles, France

Acetazolamide Add-On Therapy to OSA Surgery

Phase 4

Active, not recruiting

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Acetazolamide
Drug: Placebo

First Posted Date: 2020-01-13

Last Posted Date: 2024-06-18

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 26

Registration Number: NCT04227093

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Antwerp, Belgium

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

Phase 4

Recruiting

Conditions: Sleep Disordered Breathing
Able Bodied

Interventions: Drug: Zolpidem + PAP therapy
Drug: Acetazolamide + supplemental oxygen + PAP therapy
Drug: Buspirone + PAP therapy

First Posted Date: 2019-10-08

Last Posted Date: 2025-04-10

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 200

Registration Number: NCT04118387

Locations: 🇺🇸
John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States

Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension

Early Phase 1

Completed

Conditions: Idiopathic Intracranial Hypertension

Interventions: Drug: LMWH
Drug: acetazolamide

First Posted Date: 2019-05-24

Last Posted Date: 2019-05-24

Lead Sponsor: Fayoum University

Target Recruit Count: 48

Registration Number: NCT03963336

Locations: 🇪🇬
Fayoum University Hospital, Fayoum, Egypt

Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome

Conditions: Bartter Syndrome

Interventions: Drug: Acetazolamide

First Posted Date: 2019-02-20

Last Posted Date: 2019-02-20

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 20

Registration Number: NCT03847571

Locations: 🇮🇷
Fateme Ghane Sharbaf, Mashhad, Iran, Islamic Republic of
🇮🇷
Semnan University of Medical Sciences, Semnan, Iran, Islamic Republic of
🇮🇷
Banafshe Dormansh, Tehran, Iran, Islamic Republic of

and more 1 locations